Article Details
Retrieved on: 2025-10-08 16:47:32
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
BMY's neuroscience portfolio got a boost with the FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the ...
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here